[go: up one dir, main page]

MX2023007601A - Preparacion solida oral. - Google Patents

Preparacion solida oral.

Info

Publication number
MX2023007601A
MX2023007601A MX2023007601A MX2023007601A MX2023007601A MX 2023007601 A MX2023007601 A MX 2023007601A MX 2023007601 A MX2023007601 A MX 2023007601A MX 2023007601 A MX2023007601 A MX 2023007601A MX 2023007601 A MX2023007601 A MX 2023007601A
Authority
MX
Mexico
Prior art keywords
oral solid
solid preparation
tablet
active ingredient
dosage form
Prior art date
Application number
MX2023007601A
Other languages
English (en)
Inventor
Megumi Maruyama
Makoto Matsuoka
Hiroki Ikari
Yuka Kato
Yasuhiro Matsui
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2023007601A publication Critical patent/MX2023007601A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una forma de dosificación sólida oral que comprende N2-{[1-etil-6-(4-metilfenoxi)-1H-bencimi dazol-2-il]metil}-L-alaninamida, o una sal farmacéuticamente aceptable de éste, o un hidrato o solvato de éste como un ingrediente activo, que tiene buena disolución y estabilidad en almacenamiento; cuando la forma de dosificación sólida oral es una tableta, la tableta se puede preparar mientras se inhiben los problemas en la formación de tabletas desde un bajo contenido hasta un alto contenido del ingrediente activo.
MX2023007601A 2020-12-23 2021-12-22 Preparacion solida oral. MX2023007601A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020213086 2020-12-23
PCT/JP2021/047561 WO2022138717A1 (ja) 2020-12-23 2021-12-22 経口固形製剤

Publications (1)

Publication Number Publication Date
MX2023007601A true MX2023007601A (es) 2023-07-10

Family

ID=82159788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007601A MX2023007601A (es) 2020-12-23 2021-12-22 Preparacion solida oral.

Country Status (10)

Country Link
US (1) US20240100022A1 (es)
EP (1) EP4268816A4 (es)
JP (1) JPWO2022138717A1 (es)
KR (1) KR20230124655A (es)
CN (1) CN116615184A (es)
AU (1) AU2021410896A1 (es)
CA (1) CA3199523A1 (es)
IL (1) IL303789A (es)
MX (1) MX2023007601A (es)
WO (1) WO2022138717A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036496A1 (en) * 2023-08-17 2025-02-20 Lts Lohmann Therapie-Systeme Ag Oral thin film comprising lurasidone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558861Y2 (es) 1975-12-23 1980-02-27
KR101552033B1 (ko) * 2005-05-26 2015-09-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약학 조성물
US8778392B2 (en) * 2007-03-13 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
DK2380881T3 (en) * 2008-12-26 2017-05-08 Sumitomo Dainippon Pharma Co Ltd NEW BICYCLIC HETEROCYCLIC COMPOUND
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規２環性複素環化合物からなる医薬
US11413295B2 (en) * 2016-03-31 2022-08-16 Intercept Pharmaceuticals, Inc. Oral preparation of obeticholic acid
JP2018184382A (ja) * 2017-04-27 2018-11-22 高田製薬株式会社 エゼチミブ含有錠剤およびその製法
JP7316777B2 (ja) * 2017-06-30 2023-07-28 キッセイ薬品工業株式会社 光安定性に優れたシロドシン含有経口固形製剤
US20210369624A1 (en) * 2018-06-01 2021-12-02 Sumitomo Dainippon Pharma Co., Ltd. Solid oral dosage form having excellent dissolution properties
BR112021000183A8 (pt) 2018-07-19 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Preparação medicinal para uso externo
JP7322475B2 (ja) * 2019-04-04 2023-08-08 ニプロ株式会社 アジルサルタンを含有する錠剤

Also Published As

Publication number Publication date
KR20230124655A (ko) 2023-08-25
CN116615184A (zh) 2023-08-18
WO2022138717A1 (ja) 2022-06-30
EP4268816A4 (en) 2024-12-04
IL303789A (en) 2023-08-01
US20240100022A1 (en) 2024-03-28
CA3199523A1 (en) 2022-06-30
JPWO2022138717A1 (es) 2022-06-30
EP4268816A1 (en) 2023-11-01
AU2021410896A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
ES2646816T3 (es) Composiciones de dosificaciones orales de liberación retardada que contienen CDDO-Me amorfo
ES2864352T3 (es) Combinaciones farmacéuticas
FI2508188T3 (fi) Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
NZ753904A (en) Compositions and methods for treating anemia
SI2529622T1 (en) Bruton tyrosine kinase inhibitors
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
BR112015004244A2 (pt) composição médica oralmente administrada
PE20151905A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprende inhibidor de hmg-coa reductasa e irbesartan
PE20160011A1 (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada
UA116334C2 (uk) Тверді форми дозування бендамустину
NZ711179A (en) Oral formulations of deferasirox
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
CL2017001186A1 (es) Comprimido multicapa que contiene un fármaco inestable a la luz
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
RU2016103764A (ru) Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан
MX2023007601A (es) Preparacion solida oral.
AR108897A1 (es) Una película de desintegración oral de acción rápida para la administración de anestesia local
RU2015143475A (ru) Продукт и способ лечения диареи
PH12022550430A1 (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
RU2012136190A (ru) Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента
BR112023003572A2 (pt) Formulação oral sólida de utidelona
JP2017515858A5 (es)